The aim is to track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (index). The index is based on the MSCI ACWI IMI Index (Parent Index) and is designed to reflect the performance of the shares of large, medium, and small-capitalisation companies globally that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector.
Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.
Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
© 2026 Freetrade, All rights reserved. The Apple logo is a trademark of Apple Inc. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.
